Clinical trial
Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
NCT01696123 is registered in ClinicalTrials.gov with Shahid Beheshti University of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
- Lead sponsor
- Shahid Beheshti University of Medical Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- August 31, 2012
- Enrollment
- 125 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.